You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
Help Center
uSMARTPORT
Download
About
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsInformation about Individual Stocks

Brii Biosciences Limited (02137)

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody

Business Collaboration
Register now

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
Email: cs@usmart.hk
WhatsApp: +852 5989 2641
uSMART-Facebook-Page
Headquarters
Sheung Wan
Address:
Room 2405-06, 24/F, 308 Central Des Voeux, Sheung Wan, Hong Kong
(3-mins walk from MTR Sheung Wan Station Exit A2)
North District
Address:
1718-1721, Level 17 Landmark North, 39 Lung Sum Avenue, Sheung Shui, New Territories, Hong Kong
(5-mins walk from MTR Sheung Shui Station Exit A4)
Investment Banking
Admiralty
Address:
Room 2602A, 26/F, Tower 1, Lippo Centre, 89 Queensway, Admiralty, Hong Kong
(3-mins walk from MTR Admiralty Exit B)
uSMART Network
uSmart Securities Limited is a corporation licensed by the Hong Kong Securities and Futures Commission (CE No.: BJA907) and is authorised to carry on Type 1 (Dealing in Securities), Type 2 (Dealing in Futures Contracts), Type 4 (Advising on Securities), Type 5 (Advising on Futures Contracts), Type 6 (Advising on Corporate Finance) and Type 9 (Asset Management) regulated activities.